VBI Vaccines Inc (VBIV) : Twin Focus Capital Partners added new position in VBI Vaccines Inc during the most recent quarter end. The investment management firm now holds 20,241 shares of VBI Vaccines Inc which is valued at $72,058 , the company said in a statement filed on Aug 11, 2016 with the SEC.VBI Vaccines Inc makes up approximately 0.05% of Twin Focus Capital Partners’s portfolio.
Other Hedge Funds, Including , Perceptive Advisors added VBIV to its portfolio by purchasing 3,058,433 company shares during the most recent quarter which is valued at $10,888,021. VBI Vaccines Inc makes up approx 0.80% of Perceptive Advisors’s portfolio. Tower Research Capital (trc) added VBIV to its portfolio by purchasing 400 company shares during the most recent quarter which is valued at $1,424. Vanguard Group Inc added VBIV to its portfolio by purchasing 358,275 company shares during the most recent quarter which is valued at $1,275,459. Blackrock Investment Management added VBIV to its portfolio by purchasing 3,650 company shares during the most recent quarter which is valued at $12,994. Klingman Associates added VBIV to its portfolio by purchasing 4,895 company shares during the most recent quarter which is valued at $18,454. VBI Vaccines Inc makes up approx 0.01% of Klingman Associates’s portfolio.
VBI Vaccines Inc opened for trading at $3.75 and hit $3.8 on the upside on Tuesday, eventually ending the session at $3.76, with a gain of 0.27% or 0.01 points. The heightened volatility saw the trading volume jump to 26,286 shares. Company has a market cap of $136 M.
Many Wall Street Analysts have commented on VBI Vaccines Inc. VBI Vaccines Inc was Initiated by Ladenburg Thalmann to “Buy” on Jul 26, 2016.
VBI Vaccines Inc. formerly Paulson Capital Corp. is a biopharmaceutical company. The Company is engaged in the formulation development and delivery of vaccines that expand and enhance vaccine protection. The Company’s eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The Company has initiated work for manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s Lipid Particle Vaccine technology (LPV) is a vaccine formulation technology that enables the thermostabilization of vaccines through a formulation and freeze-drying process. The company has completed proof of concept thermostability studies on a number of vaccine and biologic targets.